Guidant starts bifurcated stent trial:
This article was originally published in Clinica
Executive Summary
Guidant has begun an international clinical study of its Multi-Link Frontier coronary stent system, which is specifically designed to treat atherosclerotic lesions at the site of a bifurcation - ie where one vessel branches from another. The trial, which is being conducted at 15 centres in nine countries, is expected to enrol 100 patients with de novo (previously untreated) or restenotic bifurcation lesions. Around 20% of patients treated for coronary artery disease are treated for bifurcated lesions, the firm notes.